<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03422081</url>
  </required_header>
  <id_info>
    <org_study_id>2012_61</org_study_id>
    <secondary_id>2013-A00830-45</secondary_id>
    <nct_id>NCT03422081</nct_id>
  </id_info>
  <brief_title>Growth and Asymmetric diMethylArginine</brief_title>
  <acronym>GAMMA</acronym>
  <official_title>Validation of the Dosage of Asymmetric Dimethylarginine (ADMA) Plasma in the Assessment of Endothelial Dysfunction During Growth Hormone Deficiency and Intrauterine Growth Retardation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Lille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Lille</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Principal objective : Validation of a handy biochemical parameter, plasma concentration of&#xD;
      Asymmetric DimethylArginine (ADMA), based on a recognize biochemical parameter, the dilation&#xD;
      of the brachial artery, at ultrasound examination, after the deflation of a cushion to&#xD;
      evaluate artery dysfunction (vascular suffering) in growth diseases, growth hormone&#xD;
      deficiency (GHD) and intrauterine growth retardation (IUGR)&#xD;
&#xD;
      Secondary objectives:&#xD;
&#xD;
        -  Comparison of ADMA plasma concentrations with dose of matched healthy control children&#xD;
&#xD;
        -  Investigation of the mechanisms of arterial dysfunction, inflammation, oxidative stress&#xD;
           and insulin resistance.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma Asymmetric Dimethylarginine (ADMA)</measure>
    <time_frame>At baseline</time_frame>
    <description>Correlation between ADMA (Asymmetric DimethylArginine, a collateral derivate of nitric oxide metabolism) levels and the percentage of dilation of the brachial artery at Doppler ultrasound examination.&#xD;
The dosage will be performed by high pressure liquid chromatography followed by tandem mass spectrometry (HPLC-MS / MS)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of dilation of the brachial artery at Doppler ultrasound examination.</measure>
    <time_frame>At baseline.</time_frame>
    <description>Correlation between ADMA (Asymmetric DimethylArginine, a collateral derivate of nitric oxide metabolism) levels and the percentage of dilation of the brachial artery at Doppler ultrasound examination.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Difference of ADMA concentration between the patient and the control groups</measure>
    <time_frame>At baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of ADMA levels with diverse cardiovascular risk factors</measure>
    <time_frame>At baseline</time_frame>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">23</enrollment>
  <condition>Growth Hormone Deficiency</condition>
  <condition>Small-for-gestational Age</condition>
  <arm_group>
    <arm_group_label>growth hormone deficiency</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>small for gestational age</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>matched controls</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>arterial doppler ultrasound</intervention_name>
    <description>doppler ultrasound</description>
    <arm_group_label>growth hormone deficiency</arm_group_label>
    <arm_group_label>matched controls</arm_group_label>
    <arm_group_label>small for gestational age</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        pediatric patients with growth disorders and matched control children&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Group A: GHD, defined by 2 GH peaks less than 6.6 ng/ml (20 mU/L) at two stimulation&#xD;
             tests&#xD;
&#xD;
          -  Group B: IUGR, defined by a birth length and/or a birth weight inferior to - 2 SD for&#xD;
             gestational age according to Usher and McLean charts&#xD;
&#xD;
          -  Group C: Control children matched to children matched to subjects of groups A and B,&#xD;
             according to gender and age&#xD;
&#xD;
          -  Informed consent signed by representative of the parental authority&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Chronic disabling disease (ex: diabetes, severe asthma)&#xD;
&#xD;
          -  Evolving cancer&#xD;
&#xD;
          -  Severe psychiatric disorder (ex: autism, schizophrenia; severe depression)&#xD;
&#xD;
          -  Hypothalamic tumor (ex: craniopharyngioma)&#xD;
&#xD;
          -  Anamnesis of cranial irradiation&#xD;
&#xD;
          -  Overweight, obesity or thinness&#xD;
&#xD;
          -  Precocious puberty&#xD;
&#xD;
          -  Non-replacing therapy by glucocorticoids or sex steroids less than 1 month before the&#xD;
             exploration&#xD;
&#xD;
          -  Anterior treatment by recombinant human GH&#xD;
&#xD;
          -  Other conditions, treatments or habits impacting arterial reactivity: acrocyanosis,&#xD;
             cryoglobulinemia, beta adrenergic blocking habits, tobacco smoking or other drug&#xD;
             addictions, dyslipidemia&#xD;
&#xD;
          -  Pregnancy or lactation&#xD;
&#xD;
          -  Acute infection less than three weeks before the investigation&#xD;
&#xD;
          -  Participation to a therapeutic protocol&#xD;
&#xD;
          -  Impossibility for the representatives of the parental authority to understand the&#xD;
             objectives of the protocol&#xD;
&#xD;
          -  Absence of social security coverage. Refusal by the parents to sign the informed&#xD;
             consent or oral refusal by the child to participate to the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jacques Weill, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Lille</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>HÃ´pital Jeanne de Flandre - CHRU de Lille</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Purpan</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>January 10, 2018</study_first_submitted>
  <study_first_submitted_qc>February 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 5, 2018</study_first_posted>
  <last_update_submitted>August 24, 2020</last_update_submitted>
  <last_update_submitted_qc>August 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>endothelial dysfunction</keyword>
  <keyword>doppler ultrasound examination</keyword>
  <keyword>nitric oxide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dwarfism, Pituitary</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

